{"title":"P53 Protein (TP53): Target Overview, Research Applications, and Selection Guide","description":"","products":[{"product_id":"recombinant-human-p53-protein-his-tag-bl-113pc","title":"Recombinant Human p53 Protein (His Tag)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_000546\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHomo sapiens Mdm2 p53 binding protein homolog (mouse) (MDM2); hdm2; HDMX; MGC5370 and MGC71221.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman p53 protein is composed of 393 amino acid residues with several distinct regions. The N-terminal activation domain allows p53 protein to recruit the basal transcription machinery and activate the expression of target genes. The core domain binds to target DNA in a sequence-specific manner and the majority of mutations found in human tumors occur in the region of the gene encoding this domain (1-3). The C-terminal domain is composed of predominantly basic residues and modification of the C-terminal basic domain, including acetylation, glycosylation and phosphorylation, is an essential mechanism for regulating p53 function (4-6). Disruption or loss of oligomerization function is associated with loss of cell cycle arrest (5, 6). This mutant protein (with the deletion of the C-terminus 51 residues including the entire basic domain and a portion of the tetramerization domain) can be used as a unique tool to study specific functions of p53 related to the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein was expressed in Baculovirus-insect cell. This protein is fused with a His tag and purified using our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBaculovirus-insect cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eEPQSDPSVEP PLSQETFSDL WKLLPENNVL SPLPSQAMDD LMLSPDDIEQ WFTEDPGPDE APRMPEAAPP VAPAPAAPTP AAPAPAPSWP LSSSVPSQKT YQGSYGFRLG FLHSGTAKSV TCTYSPALNK MFCQLAKTCP VQLWVDSTPP PGTRVRAMAI YKQSQHMTEV VRRCPHHERC SDSDGLAPPQ HLIRVEGNLR VEYLDDRNTF RHSVVVPYEP PEVGSDCTTI HYNYMCNSSC MGGMNRRPIL TIITLEDSSG NLLGRNSFEV RVCACPGRDR RTEEENLRKK GEPHHELPPG STKRALPNNT SSSPQPKKKP LDGEYFTLQI RGRERFEMF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e39.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90% purity by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt;0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein was kept in 20 mM Tris-Cl (pH 8.0), 20% glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eStored the protein at -70°C before use. Avoid repeated freeze thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877086466273,"sku":"BL-113PC","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-p53-protein-his-tag-bl-114pc","title":"Recombinant Human p53 Protein (His Tag)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_000546\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHomo sapiens Mdm2 p53 binding protein homolog (mouse) (MDM2); hdm2; HDMX; MGC5370 and MGC71221.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein was expressed in Baculovirus-insect cell. This protein is fused with a His tag and purified using our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBaculovirus-insect cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eEAPRMPEAAP PVAPAPAAPT PAAPAPAPSW PLSSSVPSQK TYQGSYGFRL GFLHSGTAKS VTCTYSPALN KMFCQLAKTC PVQLWVDSTP PPGTRVRAMA IYKQSQHMTE VVRRCPHHER CSDSDGLAPP QHLIRVEGNL RVEYLDDRNT FRHSVVVPYE PPEVGSDCTT IHYNYMCNSS CMGGMNRRPI LTIITLEDSS GNLLGRNSFE VRVCACPGRD RRTEEENLRK KGEPHHELPP GSTKRALPNN TSSSPQPKKK PLDGEYFTLQ IRGRERFEMF RELNEALELK DAQAGKEPGG SRAHSSHLKS KKGQSTSRHK KLMFKTEGPD SD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e45.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90% purity by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt;0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein is stored in 20 mM Tris-Cl (pH 8.0), 20% Glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA buffer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eStored the protein at -70°C before use. Avoid repeated freeze thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877087383777,"sku":"BL-114PC","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-p53-protein-his-tag-bl-122pc","title":"Recombinant Human p53 Protein (His Tag)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_000546\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHomo sapiens Mdm2 p53 binding protein homolog (mouse) (MDM2); hdm2; HDMX; MGC5370 and MGC71221.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman p53 protein is composed of 393 amino acid residues with several distinct regions. The N-terminal activation domain allows p53 protein to recruit the basal transcription machinery and activate the expression of target genes. The core domain binds to target DNA in a sequence-specific manner and the majority of mutations found in human tumors occur in the region of the gene encoding this domain (1-3). The C-terminal domain is composed of predominantly basic residues and modification of the C-terminal basic domain, including acetylation, glycosylation and phosphorylation, is an essential mechanism for regulating p53 function (4-6). Disruption or loss of oligomerization function is associated with loss of cell cycle arrest (5, 6). This mutant protein (with the deletion of the C-terminus 51 residues including the entire basic domain and a portion of the tetramerization domain) can be used as a unique tool to study specific functions of p53 related to the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein was expressed in Baculovirus-insect cell. This protein is fused with a His tag and purified using our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBaculovirus-insect cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eEPQSDPSVEP PLSQETFSDL WKLLPENNVL SPLPSQAMDD LMLSPDDIEQ WFTEDPGPDE APRMPEAAPP VAPAPAAPTP AAPAPAPSWP LSSSVPSQKT YQGSYGFRLG FLHSGTAKSV TCTYSPALNK MFCQLAKTCP VQLWVDSTPP PGTRVRAMAI YKQSQHMTEV VRRCPHHERC SDSDGLAPPQ HLIRVEGNLR VEYLDDRNTF RHSVVVPYEP PEVGSDCTTI HYNYMCNSSC MGGMNRRPIL TIITLEDSSG NLLGRNSFEV RVCACPGRDR RTEEENLRKK GEPHHELPPG STKRALPNNT SSSPQPKKKP LDGEYFTLQI RGRERFEMF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e39.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90% purity by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt;0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein was kept in 20 mM Tris-Cl (pH 8.0), 20% glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eStored the protein at -70°C before use. Avoid repeated freeze thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877101965537,"sku":"BL-122PC","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-p53-protein-bl-1365sg","title":"Recombinant Human p53 Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_000546\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53, LFS1, TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53 is a key regulator of cell growth and acts as a tumor suppressor gene. Wild-type p53 gene can suppress transformation of rat embryo fibroblasts in cell culture by other oncogenes such as the adenovirus E1A and Ras (1). DNA tumor viruses such as SV40 large T antigen and the adenovirus E1A plus E1B-55Kd proteins bind to p53 and inactivate its tumor suppressor activities leading to cellular transformation. Mutational inactivation of the p53 gene is detected in more than 50% of human cancers. Mutation of p53 renders cancer cells more resistant to current cancer therapies due to lack of p53-mediated apoptosis (2).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant full-length human p53 was produced in E. coli system, fused with a GST tag at N-terminus. This protein is purified with our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e~79 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor specific purity information on a given lot, see related COA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt; 1.0 EU per μg of the protein as determined by the LAL method\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant protein is stable for up to 12 months at -70°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein should be stored should be stored at \u0026lt; -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877125034209,"sku":"BL-1365SG","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-p53-protein-bl-1406sg","title":"Recombinant Human p53 Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_000546\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53, LFS1, TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53 is a key regulator of cell growth and acts as a tumor suppressor gene. Wild-type p53 gene can suppress transformation of rat embryo fibroblasts in cell culture by other oncogenes such as the adenovirus E1A and Ras (1). DNA tumor viruses such as SV40 large T antigen and the adenovirus E1A plus E1B-55Kd proteins bind to p53 and inactivate its tumor suppressor activities leading to cellular transformation. Mutational inactivation of the p53 gene is detected in more than 50% of human cancers. Mutation of p53 renders cancer cells more resistant to current cancer therapies due to lack of p53-mediated apoptosis (2).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant full-length human p53 was produced by baculovirus in Hi5 cells, fused with a GST tag at N-terminus. This protein is purified with our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHi5 cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e~79 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor specific purity information on a given lot, see related COA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt; 1.0 EU per μg of the protein as determined by the LAL method\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant protein is stable for up to 12 months at -70°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human p53 Protein should be stored should be stored at \u0026lt; -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877131096289,"sku":"BL-1406SG","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-tp53rk-protein-bl-1509sg","title":"Recombinant Human TP53RK Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNM_033550\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBUD32; C20orf64; dJ101A2; Nori-2; Nori-2p\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53RK or TP53 regulating kinase and also called PRPK (p53-related protein kinase) is the human homologue of yeast Bud32. TP53RK belongs to a small subfamily of atypical protein kinases. TP53RK is expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes and lower expression of TP53RK is found in heart, kidney, and spleen (1). PRPK interacts with CGI-121 and co-precipitation of p53 with PRPK is inhibited by adding recombinant CGI-121 in vitro. CGI-121 may act as an inhibitor of the PRPK-p53 interaction (2). TP53RK is activated by another kinase, Akt\/PKB, which phosphorylates TP53RK at Ser250.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant full-length human TP53RK was produced by baculovirus in Sf9 insect cells, fused with a GST tag at N-terminus. This protein is purified with our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSf9 insect cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAA Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e~55 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor specific purity information on a given lot, see related COA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt; 1.0 EU per μg of the protein as determined by the LAL method\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant protein is stable for up to 12 months at -70°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human TP53RK Protein should be stored should be stored at \u0026lt; -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42877156360417,"sku":"BL-1509SG","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-hla-a-0201-tp53-complex-protein-c-10his-bl-2642np","title":"Recombinant Human HLA-A*0201 TP53 complex Protein (C-10His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human HLA-A*0201 TP53 complex Protein is produced by our Mammalian expression system and the target gene encoding (HMTEVVRHC)(R175H)\u0026amp;Ile21-Met119\u0026amp;Gly25-Ile308 (Ala269Val) is expressed with a 10His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP61769\u0026amp;A0A140T913\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC, HLA-A*0201 TP53 complex Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCellular tumor antigen p53, is also known as TP 53, is the most frequently mutated gene across all cancers and encodes the tumor suppressor p53 protein. There is a neoepitope of TP53 which is p53R175H HMTEVVRHC. TP53 protein is degraded by the proteasome into peptides, some of which can be presented on the cell surface by human leukocyte antigen (HLA). The p53R175H \/HLA-A*02:01 complex is a particularly attractive therapeutic target, shared by many cancer patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e49.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50-65 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, 1mM EDTA, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43911648051425,"sku":"BL-2642NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLTWAB7CUAACg2TM27qo157.jpg?v=1685850182"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-00984p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Baculovirus expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e(Antigen NY-CO-13)(Phosphoprotein p53)(Tumor suppressor p53)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa(Y220C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e49.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998449565921,"sku":"BLC-00984P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP024077HU_M1_-SDS.jpg?v=1690496858"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-00987p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Baculovirus expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e(Antigen NY-CO-13)(Phosphoprotein p53)(Tumor suppressor p53)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVHVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa(R273H)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e49.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":45919851053281,"sku":"BLC-00987P","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP024077HU_M3_-SDS.jpg?v=1690496869"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-00988p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Baculovirus expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e(Antigen NY-CO-13)(Phosphoprotein p53)(Tumor suppressor p53)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRHCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa(R175H)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e49.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998450024673,"sku":"BLC-00988P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP024077HU_M2_-SDS.jpg?v=1690496872"},{"product_id":"recombinant-rat-cellular-tumor-antigen-p53-tp53-protein-his-blc-02323p","title":"Recombinant Rat Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P10361          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTp53; P53; Cellular tumor antigen p53; Tumor suppressor p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEDSQSDMSIELPLSQETFSCLWKLLPPDDILPTTATGSPNSMEDLFLPQDVAELLEGPEEALQVSAPAAQEPGTEAPAPVAPASATPWPLSSSVPSQKTYQGNYGFHLGFLQSGTAKSVMCTYSISLNKLFCQLAKTCPVQLWVTSTPPPGTRVRAMAIYKKSQHMTEVVRRCPHHERCSDGDGLAPPQHLIRVEGNPYAEYLDDRQTFRHSVVVPYEPPEVGSDYTTIHYKYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENFRKKEEHCPELPPGSAKRALPTSTSSSPQQKKKPLDGEYFTLKIRGRERFEMFRELNEALELKDARAAEESGDSRAHSSYPKTKKGQSTSRHKKPMIKKVGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-391aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e47.5kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            rno:24842           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000047840           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28131915            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            these findings indicated that miR31a5p is involved in hypertension via the accelerated proliferation of arterial smooth muscle cells and inhibition of apoptosis through targeting TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29620173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed initial downregulation in the expression of p53 protein during breast cancer development. However, with progression towards malignancy, upregulation of p53 was observed. These changes were associated with polymorphism in p53 gene, which was detected in exon 5.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29498408            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Compared with the saline Hepatocellular carcinoma (HCC)-group, transplantation with CD34+ human hematopoietic stem cells produced a further increase in the levels of wnt4 (+19.4%) and p53 gene expression (+53%), a 2-fold increase in the percentage of cancer progenitor cells and increased HCC pathology grading            \u003ca rel=\"nofollow\"\u003e             PMID:                        29429512            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results indicate that the miR-188-3p-MDM2-p53 axis may have a critical role in sevoflurane-induced cognitive dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29344658            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MiR-31a-5p protects cardiomyocytes against angiotensin II-induced apoptosis by targeting Tp53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29286111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that Delta40p53 can be generated by a 20S proteasome-mediated post-translational mechanism so as to control p53 function.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885617            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested that caveolin1 may be involved in nucleus pulposus cellular senescence during oxidative stress in vitro, mainly via the p53\/p21 signaling pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29039595            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our results revealed that the upregulation of p53 and possibly other anti-oncogenes may provide a potential effective therapeutic strategy for malignant pheochromocytoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        29048679            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            over-expression of p53 could mediate oligodendrocyte apoptosis thus resulting in demyelination in two ways; by enhancing ER-mitochondria interaction and by triggering the E2F1 mediated apoptosis pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28237798            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Effect of polydatin on expression of p53 and Notch1 in brain tissue of ischemic cerebrovascular disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29504377            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            pharmacological inhibition of ATM kinase (KU55933) reduced activation of ATM kinase, but not p53, suggesting that HG-mediated activation of p53 and ATM could represent independent pro-apoptotic events..these data indicate that sustained activation of Rac1-p38MAPK signaling axis leads to activation of p53 leading to beta-cell dysfunction under the duress of chronic hyperglycemic conditions            \u003ca rel=\"nofollow\"\u003e             PMID:                        28220272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            JNK\/p53 pathway might play a critical role in the tubular cell apoptosis induced by -MCPD 1-palmitate.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27008853            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the Ras\/Raf\/Erk signals contribute to neuronal death through the phosphorylation of p53 in hippocampus after subarachnoid hemorrhage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26497030            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hypoxia and hyperoxia differentially control proliferation of rat neural crest stem cells via distinct regulatory pathways of the HIF1alpha-CXCR4 and TP53-TPM1 proteins            \u003ca rel=\"nofollow\"\u003e             PMID:                        28002632            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study determined if dietary restriction (DR) protects against hypoxic-ischemia (HI) in the neonatal brain via insulin receptor substrate-1 (IRS-1)\/Akt pathway-mediated downregulation of p53 in the neurovascular unit.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26111627            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that the cancer-inhibitory activity of sodium butyrate and its derivatives on liver carcinogenesis may be attributed to retention of p53 and CRM1 proteins in the nucleus, an event that may trigger activation of p53-mediated apoptotic cell death in neoplastic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27013579            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Fischer model is more consistent with the early onset of bone and central nervous system sarcomas found in humans with germline Tp53 mutations.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27528400            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings reveal a novel function of p53 in controlling inflammatory responses and suggest that p53 abnormalities in rheumatoid arthritis could sustain and accelerate synovial inflammation            \u003ca rel=\"nofollow\"\u003e             PMID:                        27881147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mammalian SOS response is characterized by an increase in the p53 gene with activation of multiple DNA repair genes that harbor p53 response elements in their promoters.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28800961            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Doxorubicin (Dox)-administration to cardiomyocytes increased the levels of reactive oxygen species (ROS) in a time-dependent manner that followed the activation of stress-induced proteins p53, p38 and JNK MAPKs, culminating in an increase in autophagy and apoptosis markers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28678856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ANXA1 interacts with p53 and promotes p53 transcriptional activity, which in turn regulates Bid expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27584794            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            transformed MSCs express high levels of a p53 mutant that loses the ability to bind survivin gene            \u003ca rel=\"nofollow\"\u003e             PMID:                        27046449            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            an Ntv-a transgenic rat colony was established and used to study glial brain tumors driven by two well-characterized oncogenic gene transformations, PDGFA overexpression and p53 depletion. Combined PDGFA and p53 alterations resulted in large, heterogeneous tumors in all affected animals            \u003ca rel=\"nofollow\"\u003e             PMID:                        28358926            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MEG3 could interacted with p53 and regulated its expression, and p53 exerted significant binding in the promoters for NOX4, suggesting that MEG3 regulated NOX4 expression via p53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28634073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The miR-34a\/SIRT1\/p53 signaling pathway is activated in hepatocytes but not hepatic stellate cells during liver fibrosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27387128            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MDM2 is involved in fibroblast activation, mediating renal tubulointerstitial fibrosis via a p53-independent pathway dependant on Notch1 ubiquitination and proteasome degradation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100501            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicates that Drp1 mediates compression-induced programmed necrosis of NP cells by promoting mitochondrial translocation of p53 and nuclear translocation of AIF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28411026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Formononetin prevents cisplatin-induced acute kidney injury by targeting Oct2\/TP53 in the kidney.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28414026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Alloxan-induced renal damage is associated with alterations of p53, TGF-beta1, and extracellular matrix metalloproteinases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28220578            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Taken together, these results indicated that ALA protected dopaminergic neurons against MPP+induced neurotoxicity through its ability to upregulate the DNA repair protein, PCNA, via the P53 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27665784            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 attenuates cerebral ischemia\/reperfusion-induced injury by targeting the p53\/microRNA-22 axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27878231            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cholesterol regulates bone marrow mesenchymal stem cell senescence by modulating cell cycle, autophagy, and the ROS\/p53\/p21(Cip1\/Waf1) signaling pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27703600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that dysregulation of miR-30c and miR-181a may be involved in upregulation of p53-p21 pathway in diabetes induced cardiac hypertrophy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27221738            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-449 regulates the SIRT1\/p53\/BAX pathway, which may be its possible mechanism in modulating cell apoptosis of cisplatin-induced Acute kidney injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26968221            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In conclusion, Cabin1 expression significantly increases during podocyte injury. Knockdown of Cabin1 induces p53 expression decrease in cultured podocyte. Cabin1 may provide a new target to investigate podocyte injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26400065            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 regulates autophagic activity in senescent rat mesenchymal stromal cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26792455            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This indicates that MPP+-induced oxidative damage is mediated by the downregulation of PCNA through the p53 pathway in a cellular model of Parkinson's disease .            \u003ca rel=\"nofollow\"\u003e             PMID:                        26677001            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results of the present study therefore indicated that resveratrol protected H9c2 cells from DOX-induced apoptosis via the AMPK\/P53 pathway            \u003ca rel=\"nofollow\"\u003e             PMID:                        26675978            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hypoxia response element Bcl2 inhibition can effectively attenuate hypoxia-induced apoptosis resistance in pulmonary microvascular endothelial cells by downregulating Bcl2 expression and upregulating caspase-3 and P53 expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26456506            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study suggested that neonatal bronchopulmonary dysplasia caused impaired cognitive function and neuron apoptosis in hippocampus via p53 and HIF-1alpha            \u003ca rel=\"nofollow\"\u003e             PMID:                        26431790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-23a binds to p53 and enhances its association with miR-128 promoter            \u003ca rel=\"nofollow\"\u003e             PMID:                        26553132            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hydrogen-rich saline is able to protect against AKI after liver transplantation partly by reducing apoptosis, which is possibly involved in the modulation of p53-mediated autophagy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26714124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest the existence of a causal link between Cox-2 and p53, which may represent a toxic mechanism of electrophilic lipid peroxidation products.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25506925            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Autoimmune Optic Neuritis Is Associated with Altered APP Cleavage in Neurons and Up-Regulation of p53            \u003ca rel=\"nofollow\"\u003e             PMID:                        26426258            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings show p53 is activated in astrocytes during ischemia and that inhibition of the activity of this molecule prevents not only oxygen-glucose deprivation-induced neuronal and astrocytic death but also astrocyte activation and impaired glutamate uptake            \u003ca rel=\"nofollow\"\u003e             PMID:                        26302161            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of BACE1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25773675            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Phosphorylation of p53 by LRRK2 induces p21(WAF1\/CIP1) expression and apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26384650            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Diabetes upregulates p21(CIP1\/Waf1) signaling in testicular germ cells in association with alteration in p-p53ser315 expression, probably to counteract DNA damage-induced cell death.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24828139            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results also suggest that chromothripsis primarily occurs under p53 heterozygous rather than p53 null conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25811670            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998590238945,"sku":"BLC-02323P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-RP155094r-SDS.jpg?v=1690501279"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-sumo-blc-03068p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAntigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; P53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; tumor antigen p55; Tumor protein 53; Tumor protein p53; Tumor suppressor p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e59.7kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998663639265,"sku":"BLC-03068P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP024077HU-SDS.jpg?v=1690562344"},{"product_id":"recombinant-mouse-cellular-tumor-antigen-p53-tp53-protein-his-sumo-blc-04263p","title":"Recombinant Mouse Cellular Tumor Antigen P53 (TP53) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Cellular Tumor Antigen P53 (TP53) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P02340          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTp53; P53; Trp53; Cellular tumor antigen p53; Tumor suppressor p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMus musculus (Mouse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEESQSDISLELPLSQETFSGLWKLLPPEDILPSPHCMDDLLLPQDVEEFFEGPSEALRVSGAPAAQDPVTETPGPVAPAPATPWPLSSFVPSQKTYQGNYGFHLGFLQSGTAKSVMCTYSPPLNKLFCQLAKTCPVQLWVSATPPAGSRVRAMAIYKKSQHMTEVVRRCPHHERCSDGDGLAPPQHLIRVEGNLYPEYLEDRQTFRHSVVVPYEPPEAGSEYTTIHYKYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENFRKKEVLCPELPPGSAKRALPTCTSASPPQKKKPLDGEYFTLKIRGRKRFEMFRELNEALELKDAHATEESGDSRAHSSYLKTKKGQSTSRHKKTMVKKVGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-387aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e59.2kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis, but seems to have to effect on cell-cycle regulation. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:22059           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000104298           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30308185            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Data provide evidence that p53 enhances NOXA-induced apoptosis when autophagy is inhibited.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29758299            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The p53 is critical in activation of T lymphocytes not only by regulating proliferation and apoptosis but also because of its effective function in the pathogenesis of septic complications.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30453300            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show an association of PD with p53 and active caspase-3 overexpression and beta-adrenergic receptor underexpression in the heart, potentially promoting the cardiac autonomic dysfunction frequently observed in PD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30135418            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results show that ischemic preconditioning increased neuronal MDM2 protein levels, which prevented ischemia-induced p53 stabilization and neuronal death.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In studies of lymphomagenesis, mutant TRP53 drives tumorigenesis primarily through dominant-negative effects, which modulates wild-type TRP53 function in a manner advantageous for neoplastic transformation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30366906            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 deteriorated cardiac functions and cardiac hypertrophy, apoptosis, and fibrosis by partially inhibition of HIF1alpha and VEGF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29729274            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MDMX is an important regulator of p53 DNA binding, which complements the role of MDM2 in regulating p53 level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29581299            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the disruption of Mdm2\/p53 interaction affects the early-embryonic otic progenitor cells and their descendants.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28181574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Deletion of NF1 leads to mutant oligodendrocyte precursor cell (OPC) expansion through increased proliferation and decreased differentiation, the deletion of p53 impairs OPC senescence. Signaling analysis showed that, while PI3K and MEK pathways go through stepwise over-activation, mTOR signaling remains at the basal level in pre-transforming mutant OPCs but is abruptly up-regulated in tumor OPCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29392777            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings uncover a new function of p53 in the regulation of Akt signaling and reveal how p53, ASS1, and Akt are interrelated to each other.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28560349            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Rlip deficiency suppresses spontaneous malignancy in p53(-\/-) mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29572430            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Obtained results suggest that Wip1 deficiency sensitizes cells to sodium butyrate and to MEK\/ERK inhibitors independently from Wip1 main target protein - p53. Data acquired give insights into role of Wip1 in cellular responses to treatment with HDAC and MEK\/ERK inhibitors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30188093            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CYLD removes K48-linked ubiquitin chains from p53 indirectly by cleaving K63 chains, suggesting that p53 is decorated with complex ubiquitin chains.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27561390            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumor suppressor p53 functions as an essential antiviral molecule against Japanese encephalitis virus            \u003ca rel=\"nofollow\"\u003e             PMID:                        27956051            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that p53 expression and mutational status do not interfere with CES2 expression in colorectal neoplasm.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29651325            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the beta-catenin C-terminus indirectly represses p53, and this function is essential for embryogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27499244            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that the chronic inflammation due to constitutive overexpression of TNF is not sufficient to significantly accelerate tumorigenesis driven by the loss of p53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28079895            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the MDM2-p53-PC signalling axis links mitochondrial metabolism to insulin secretion and glucose homeostasis, and could represent a therapeutic target in diabetes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27265727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Comparison of lineage-related p53 knockout and wild-type clones reveals a minor role of p53 in suppressing cell expansion in lung adenomas. In contrast, p53 loss promotes both the initiation and expansion of low-grade pancreatic intraepithelial neoplasia, likely through differential expression of the p53 regulator p19ARF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27585860            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The neuroprotective effects of p53\/microRNA22 may regulate inflammation and apoptosis in in subarachnoid hemorrhage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29336471            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            wild-type p53 exerts a dominant tumor-suppressive effect on mutant tumors, as all genotypes were similarly sensitive to its restoration in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        28790158            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data demonstrate a causative role for TRP53 mutants in development of chemoresistant lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28847987            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Activation of p53 blocks neural differentiation of miRNA-deficient pluripotent stem cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29141234            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 mediates the regulation of bile acid disposition and attenuates cholic acid-induced cholestasis in mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        28910492            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data demonstrates that p53 inhibits OSX binding to their responsive Sp1\/GC-rich sites in the promoters of their osteogenic target genes, such as IBSP or COL1A1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28777372            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A summary of current knowledge of p53-mediated tumor-suppressive mechanisms gleaned from in vivo studies in mouse models (review).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29099489            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased Cdc7-dependent replication initiation is a hallmark of p53 gain-of function mutations in lung adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28887320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Aging mouse models have revealed the complexity of the p53-Mdm2 axis and have solidly placed the p53 network as being key to many aspects of both pathological aging conditions and normal aging (review).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29192902            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In myoblasts silenced for the expression of muscle regulatory transcription factor MyoD, tumor suppressor p53 binding to the PUMA promoter is diminished in response to culture in differentiation medium.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28918507            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study provides evidence that high expression of CLDN6 confers chemoresistance on breast cancer which is mediated by GSTP1, the activity of which is regulated by p53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29116019            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            AKI was associated with the upregulation of several known p53 target genes. This was attenuated in p53-KO mice.  In human renal tubular epithelial cell line, vancomycin induced p53 accumulation. p53 was associated with the development of VAN-induced AKI through upregulation of miR-192-5p.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27941921            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Recent work in a TP53(-\/-)BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not            \u003ca rel=\"nofollow\"\u003e             PMID:                        29120748            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study reports a high-incidence, low-variation spontaneous mouse model of spondyloarthropathy that delineates how the combination of inflammatory cytokine interleukin-27 (IL-27) signaling deficiency and mitogenic signaling (mutant p53R172H) in vivo, leads to bone loss in the vertebral bodies and ossification of the cartilage in the intervertebral discs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29494633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Knockdown of CITED2 led to a decreased interaction of p53 with its inhibitor MDM2, which results in increased amounts of total p53 protein. Data indicate that CITED2 functions in pathways regulating p53 activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29072699            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            his study demonstrates that inhibition of Drp1 hyperactivation by a Drp1 peptide inhibitor P110 is neuroprotective in a MPTP animal model. Our data also suggest that the protective effects of P110 treatment might be mediated by inhibiting the p53 mediated apoptotic pathways in neurons through inhibition of Drp1-dependent p53 mitochondrial translocation            \u003ca rel=\"nofollow\"\u003e             PMID:                        27619562            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results indicate that IGF-I induces senescence of hepatic stellate cells, inactivates these cells and limits fibrosis in a p53-dependent manner and that IGF-I may be applied to treat nonalcoholic steatohepatitis and cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27721459            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conditional deletion of uterine Trp53 (p53(d\/d)), molecularly linked to mTORC1 activation and causally linked to premature uterine senescence and preterm birth, results in aberrant lipid signatures within the heterogeneous cell types of embryo implantation sites on day 8 of pregnancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27620843            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that ASPP2 plays an important role in p53-mediated neuronal apoptosis under gp120 stress.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27625111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study shows that when cell death and cell cycle arrest pathways are inhibited, p53 can still mediate MGMT-dependent repair, to promote cell survival upon DNA damage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753207            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            DNA repair, mediated by DNA-PK, and cell cycle arrest, mediated by p53, cooperate to protect the stem cell niche after DNA damage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28686579            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        28652370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            in the absence of the tumor suppressor p53, germline genetic deletion of AMPK beta1 accelerates the appearance of a T-cell lymphoma that reduces lifespan compared to p53 deficiency alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28544264            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested that TAZ may suppress apoptosis and premature senescence in spermatogenic cells by inhibiting the p53-p21 signaling pathway, thus playing important roles in the maintenance and control of reproductive function.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28613007            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results illustrate the importance of the cooperative activities of p53 and Mdm2 in a network of miRNAs that function to impose a barrier against aberrant cardiomyocyte cell cycle re-entry to maintain cardiac homeostasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28745540            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these observations suggest that hypoxic preconditioning of cardiac progenitor cells could lead to p53 inhibition by up-regulating            \u003ca rel=\"nofollow\"\u003e             PMID:                        27488808            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicate the functional role of the MIF-COX-p53 axis in inflammation and cancer at the genomic and proteomic levels in COX-2-ablated cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29247872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 limits ferroptosis of colorectal cancer cells by blocking DPP4 activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28813679            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            FGF1 protects neuroblastoma cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29048426            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998810833121,"sku":"BLC-04263P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP024077MO-SDS.jpg?v=1690507382"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-06087p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa(Y220C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998994989281,"sku":"BLC-06087P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP024077HU_M_-SDS.jpg?v=1690512804"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-07377p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Baculovirus expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e46.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999182913761,"sku":"BLC-07377P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP024077HU-SDS.jpg?v=1690517628"},{"product_id":"recombinant-human-p53-regulated-apoptosis-inducing-protein-1-tp53aip1-protein-gst-blc-08675p","title":"Recombinant Human P53-Regulated Apoptosis-Inducing Protein 1 (TP53AIP1) Protein (GST)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human P53-Regulated Apoptosis-Inducing Protein 1 (TP53AIP1) Protein (GST) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q9HCN2          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53AIP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 regulated apoptosis inducing protein 1; p53-regulated apoptosis-inducing protein 1; P53AIP 1; p53AIP1; TP53AIP 1; TP53AIP1; TPIP1_HUMAN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-GST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMGSSSEVSFRSAQASCSGARRQGLGRGDQNLSVMPPNGRAQTHTPGWVSPCSENRDGLLPATAPGRLCSHRGADIPSFQTHQDPVTASGSSELHADCPQFRALDRAGN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-108aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of BC069399\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e38.3kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell Biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMay play an important role in mediating p53\/TP53-dependent apoptosis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMitochondrion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            29984           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            605426           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:63970           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000432743           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29359367            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Data indicate that p53-regulated apoptosis-inducing protein 1 (p53AIP1) inhibits the proliferation of PC-3M cells, arrests cell cycle at S\/G2-M phase, decreases the abilities of invasion and migration and promotes cell apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25108434            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These studies indicate the critical role of p53AIP1 under DNA damaging stresses for cell fate determination in rheumatoid arthritis-fibroblast-like synovioctes containing the p53R248Q mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24316591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apak competes with p53 for binding to inhibit p53AIP1 expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22334068            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            large sample size of the combined cohort rejects a high-risk effect greater than 2.2 and indicates a limited role of TP53AIP1 in prostate cancer predisposition            \u003ca rel=\"nofollow\"\u003e             PMID:                        22457820            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53AIP1 regulates the mitochondrial apoptotic pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12019168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of Ki67 and p53 in various forms of leukoplakia point to the increasing instability of the genome in parallel with the severity of leukoplakia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14707453            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression of the p53 mutant, R248Q, in liver cancer cells may enhance their drug resistance and upregulation of P-glycoprotein activity may contribute to this protective effect.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15004724            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Roscovitine induced up-regulation of p53AIP1 protein and the depolarization of mitochondrial potential.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15657359            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53AIP1 gene is important for non-small cell lung cancer progression and may be a possible prognostic marker            \u003ca rel=\"nofollow\"\u003e             PMID:                        17851056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Insufficient expression of p53AIP1 may play a role in gastric carcinogenesis in patients infected with H. pylori infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18277906            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that the combination of p53AIP1 and survivin gene expression may be a powerful tool to stratify subgroups with better or worse prognosis from the variable non-small cell lung cancer population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19228369            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999356649697,"sku":"BLC-08675P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP884624HU-SDS.jpg?v=1690521931"},{"product_id":"recombinant-human-tp53-regulated-inhibitor-of-apoptosis-1-triap1-protein-gst-blc-09140p","title":"Recombinant Human Tp53-Regulated Inhibitor Of Apoptosis 1 (TRIAP1) Protein (GST)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Tp53-Regulated Inhibitor Of Apoptosis 1 (TRIAP1) Protein (GST) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           O43715          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTRIAP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53-inducible cell-survival factor; p53CSV; Protein 15E1.1; TP53-regulated inhibitor of apoptosis 1; TRIA1_HUMAN; Triap1; WF 1; WF1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-GST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMNSVGEACTDMKREYDQCFNRWFAEKFLKGDSSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPENSS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-76aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e35.8kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell Biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInvolved in the modulation of the mitochondrial apoptotic pathway by ensuring the accumulation of cardiolipin (CL) in mitochondrial membranes. In vitro, the TRIAP1:PRELID1 complex mediates the transfer of phosphatidic acid (PA) between liposomes and probably functions as a PA transporter across the mitochondrion intermembrane space to provide PA for CL synthesis in the inner membrane. Likewise, the TRIAP1:PRELID3A complex mediates the transfer of phosphatidic acid (PA) between liposomes (in vitro) and probably functions as a PA transporter across the mitochondrion intermembrane space (in vivo). Mediates cell survival by inhibiting activation of caspase-9 which prevents induction of apoptosis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMitochondrion. Mitochondrion intermembrane space.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTRIAP1\/MDM35 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            26937           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            614943           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:51499           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000449795           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27428374            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Results describe the upregulation of TRIAP1 in drugresistant breast cancer cells. Its experimental modulation changed breast tumor cells sensitivity to doxorubicin, thus confirming its role in drug resistance.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25998939            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TRIAP1 is Conserved Specific Coregulators of the p21:PUMA Expression Ratio.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23684607            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Under specific conditions of stress, p53 regulates transcription of p53CSV and that p53CSV is one of the important players in the p53-mediated cell survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15735003            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Upregulated in at least 50% of multiple myeloma cases tested.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19171422            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HSPC132 is p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway            \u003ca rel=\"nofollow\"\u003e             PMID:                        15735003            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999399837921,"sku":"BLC-09140P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP024443HU-SDS.jpg?v=1690523340"},{"product_id":"recombinant-human-p53-and-dna-damage-regulated-protein-1-pdrg1-protein-his-sumo-blc-09954p","title":"Recombinant Human P53 And Dna Damage-Regulated Protein 1 (PDRG1) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human P53 And Dna Damage-Regulated Protein 1 (PDRG1) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q9NUG6          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDRG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDRG1; C20orf126; PDRGp53 and DNA damage-regulated protein 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMLSPEAERVLRYLVEVEELAEEVLADKRQIVDLDTKRNQNREGLRALQKDLSLSEDVMVCFGNMFIKMPHPETKEMIEKDQDHLDKEIEKLRKQLKVKVNRLFEAQGKPELKGFNLNPLNQDELKALKVILKG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-133aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e31.5kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpigenetics And Nuclear Signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMay play a role in chaperone-mediated protein folding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePrefoldin subunit beta family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            16119           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            610789           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:81572           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000202017           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27610824            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            PDRG1 was significantly increased in tumors low of miR-214.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25706919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PDRG1 expression is increased in multiple human malignancies suggesting it to be a high-value novel tumor marker that could play a role in cancer development and\/or progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21193842            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        14562055            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999479529697,"sku":"BLC-09954P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP878890HU-SDS.jpg?v=1690525903"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-10769p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAntigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; P53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; tumor antigen p55; Tumor protein 53; Tumor protein p53; Tumor suppressor p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.7kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell Biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999564824801,"sku":"BLC-10769P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP024077HU-SDS.jpg?v=1690528462"},{"product_id":"recombinant-human-cellular-tumor-antigen-p53-tp53-protein-his-blc-06484p","title":"Recombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cellular Tumor Antigen P53 (TP53) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P04637          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-393aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eApoptosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B\/ASPP1 or TP53BP2\/ASPP2 is displaced by PPP1R13L\/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL\/BMAL1-mediated transcriptional activation of PER2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.; [Isoform 1]: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; [Isoform 9]: Cytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            11998           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133239           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000269305           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30181511            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29593334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29471073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28425245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29573636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28630491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28484276            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17            \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+\/+) cells in comparison to HCT116 p53(-\/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29587790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29789628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4\/6 were significantly down-regulated upon exposure to alpha-spinasterol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29143969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29730783            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29644528            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29231257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29205062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30143034            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30473026            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29928880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            p53 knockout compensates osteopenia in murine Mysm1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29203593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29343721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        28782638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28753773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study revealed that the Wnt\/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28673515            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28194015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fifty-two percent of patients diagnosed with glioma\/glioblastoma with a positive TP53 mutation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM\/Chk\/Cdc25C\/Cdc2 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30085332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29371630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28732184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA\/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28905491            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low TP53 expression is associated with drug resistance in colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30106452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29103983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 missense mutations are associated with castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29302046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P53 degradation is mediated by COP1 in the breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29516369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28094268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 Mutation is associated with Mouth Neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28795863            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E6\/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28303973            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine\/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28348409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28294157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations            \u003ca rel=\"nofollow\"\u003e             PMID:                        29537649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model            \u003ca rel=\"nofollow\"\u003e             PMID:                        29425775            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that TP53 c.215G\u0026gt;C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29949804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29346503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53 mutations are associated with colorectal liver metastases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29937183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29893337            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":44000264487137,"sku":"BLC-06484P","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"biotinylated-human-hla-a-02-01-b2m-p53-wt-hmtevvrrc-monomer-protein-blk-00047p","title":"Biotinylated Human HLA-A*02:01\u0026B2M\u0026P53 WT (HMTEVVRRC) Monomer Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRRC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE. coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRRC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSupplied as 0.22 um filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eValid for 12 months from date of receipt when stored at -80°C.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped with dry ice.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123150381281,"sku":"BLK-00047P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20240131154523.png?v=1715128093"},{"product_id":"biotinylated-human-hla-a-02-01-b2m-p53-r175h-hmtevvrhc-monomer-protein-blk-00049p","title":"Biotinylated Human HLA-A*02:01\u0026B2M\u0026P53 R175H (HMTEVVRHC) Monomer Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus.It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRHC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE. coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSupplied as 0.22 um filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer, His Tag at 2ug\/ml (100ul\/well) on the streptavidin precoated plate (5ug\/ml). Dose response curve for Anti-HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Antibody, hFc Tag with the EC50 of 3.7ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eValid for 12 months from date of receipt when stored at -80°C.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped with dry ice.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123150676193,"sku":"BLK-00049P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20240131153459.png?v=1715128099"},{"product_id":"pe-labeled-human-hla-a-02-01-b2m-p53-wt-hmtevvrrc-tetramer-protein-blk-00383p","title":"Recombinant PE-Labeled Human HLA-A*02:01\u0026B2M\u0026P53 WT (HMTEVVRRC) Tetramer Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant PE-Labeled Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-Labeled Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRRC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 (HLA-A*02:01) Tetramer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSupplied as 0.22um filtered solution in PBS, 0.2% BSA (pH 7.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eValid for 6 months from date of receipt when stored at -80°C.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles and protect from light.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped with dry ice.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123168010465,"sku":"BLK-00383P-100UG","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"pe-labeled-human-hla-a-02-01-b2m-p53-r175h-hmtevvrhc-tetramer-protein-blk-00390p","title":"Recombinant PE-Labeled Human HLA-A*02:01\u0026B2M\u0026P53 R175H (HMTEVVRHC) Tetramer Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant PE-Labeled Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-labeled Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin.; It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in 20 mM PB, 500 mM NaCl, 0.2% BSA (pH 8.0). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1 EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized PE-Labeled Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer, His Tag at 2 ug\/ml (100 ul\/well) on the plate. Dose response curve for Anti-HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Antibody, hFc Tag with the EC50 of 3.4 ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123168403681,"sku":"BLK-00390P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20240325173521.png?v=1715129110"},{"product_id":"recombinant-human-hla-a-02-01-b2m-p53-wt-hmtevvrrc-tetramer-protein-blk-01658p","title":"Recombinant Human HLA-A*02:01\u0026B2M\u0026P53 WT (HMTEVVRRC) Tetramer Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRRC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP53 (HLA-A*02:01) Tetramer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123369107681,"sku":"BLK-01658P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20211217141846.png?v=1715133120"},{"product_id":"biotinylated-human-hla-a-02-01-b2m-p53-wt-hmtevvrrc-monomer-protein-blk-01659p","title":"Biotinylated Human HLA-A*02:01\u0026B2M\u0026P53 WT (HMTEVVRRC) Monomer Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRRC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123369926881,"sku":"BLK-01659P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1561702396312927_c75293e5-3708-48e3-b0ef-25c44b7f3cc9.png?v=1715133123"},{"product_id":"recombinant-human-hla-a-02-01-b2m-p53-wt-hmtevvrrc-monomer-protein-blk-01660p","title":"Recombinant Human HLA-A*02:01\u0026B2M\u0026P53 WT (HMTEVVRRC) Monomer Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRRC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 WT (HMTEVVRRC) Monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123371532513,"sku":"BLK-01660P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20211217140502.png?v=1715133127"},{"product_id":"human-hla-a-02-01-b2m-p53-r175h-hmtevvrhc-tetramer-protein-blk-01661p","title":"Recombinant Human HLA-A*02:01\u0026B2M\u0026P53 R175H (HMTEVVRHC) Tetramer Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus,tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRHC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRHC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Tetramer, His Tag at 5ug\/ml (100ul\/well) on the plate. Dose response curve for Anti-HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Antibody , hFc Tag with the EC50 of 9.7ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123372351713,"sku":"BLK-01661P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20220614094746.png?v=1715133130"},{"product_id":"biotinylated-human-hla-a-02-01-b2m-p53-r175h-hmtevvrhc-monomer-protein-blk-01662p","title":"Biotinylated Human HLA-A*02:01\u0026B2M\u0026P53 R175H (HMTEVVRHC) Monomer Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRHC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp;HMTEVVRHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in 20mM PB, 500mM NaCl (pH 8.0). Normally 8% trehalose \/ 8% mannitol is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Anti-HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Antibody, hFc Tag at 5ug\/ml (100ul\/well) on the plate. Dose response curve for Biotinylated Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer, His Tag with the EC50 of 0.25ug\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123372450017,"sku":"BLK-01662P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20220713104837.png?v=1715133133"},{"product_id":"human-hla-a-02-01-b2m-p53-r175h-hmtevvrhc-monomer-protein-blk-01663p","title":"Recombinant Human HLA-A*02:01\u0026B2M\u0026P53 R175H (HMTEVVRHC) Monomer Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRHC peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eA0A140T913(HLA-A*02:01)\u0026amp;P61769(B2M)\u0026amp; HMTEVVRHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRHC peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS, 100mM L-arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Anti-HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Antibody, hFc Tag at 1ug\/ml (100ul\/well) on the plate. Dose response curve for Human HLA-A*02:01\u0026amp;B2M\u0026amp;P53 R175H (HMTEVVRHC) Monomer, His Tag with the EC50 of 44.7ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ep53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123372482785,"sku":"BLK-01663P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20210831114545.png?v=1715133136"},{"product_id":"h-tp53-monoclonal-antibody-blc-06385a","title":"Mouse anti-H TP53 Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse anti-H TP53 Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in mouse using the Synthetic Peptide as the immunogen. This antibody exists as a non-conjugated isotype IgG. This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic Peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46137041223905,"sku":"BLC-06385A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-MA000208-IF-1_1e7e9bc3-1ce5-471b-b439-1f990b803684.jpg?v=1738978983"},{"product_id":"human-acetyl-tp53-k382-monoclonal-antibody-blc-06359a","title":"Mouse anti-Human Acetyl-TP53(K382) Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse anti-Human Acetyl-TP53(K382) Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against Acetyl-TP53(K382) was raised in mouse using the Synthetic Peptide as the immunogen. This antibody exists as a non-conjugated antibody. The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody has been validated on ELISA, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman, Mouse, Rat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAcetyl-TP53(K382)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic Peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46137057673441,"sku":"BLC-06359A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-MA531279-IHC-1_839d166f-c7ee-4d5d-8994-45d937fd1eb0.jpg?v=1738979514"},{"product_id":"human-tp53-monoclonal-antibody-blc-06343a","title":"mouse anti-Human TP53 monoclonal antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003emouse anti-Human TP53 monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in mouse using the Recombinant Human TP53 Protein as the immunogen. This antibody exists as a non-conjugated monoclonal antibody, purified by protein G with a purity greater than 95%. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human TP53 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%, Protein G purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232209633,"sku":"BLC-06343A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-MA0240771A0m-ICC-1.jpg?v=1738833969"},{"product_id":"human-tp53-polyclonal-antibody-blc-03005a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Recombinant Human Cellular tumor antigen p53 protein (2-393AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, purified by protein G with a purity greater than 95%. This antibody has been validated on ELISA, WB, IHC, ChIP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman, Mouse, Rat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Cellular tumor antigen p53 protein (2-393AA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%, Protein G purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, ChIP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232275169,"sku":"BLC-03005A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA07889A0Rb-ChIP.jpg?v=1738833975"},{"product_id":"human-tp53-polyclonal-antibody-blc-05519a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Peptide sequence around aa.13~17 (P-L-S-Q-E) derived from Human p53. as the immunogen. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide. This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePeptide sequence around aa.13~17 (P-L-S-Q-E) derived from Human p53.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied at 1.0mg\/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232471777,"sku":"BLC-05519A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA063047-WB-1.jpg?v=1738833981"},{"product_id":"human-tp53-polyclonal-antibody-blc-05613a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Peptide sequence around phosphorylation site of serine 315 (S-S-S(p)-P-Q) derived from Human p53. as the immunogen. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePeptide sequence around phosphorylation site of serine 315 (S-S-S(p)-P-Q) derived from Human p53.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied at 1.0mg\/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232701153,"sku":"BLC-05613A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA826876-WB-1.jpg?v=1738833988"},{"product_id":"human-tp53-polyclonal-antibody-blc-05614a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Peptide sequence around phosphorylation site of serine 46 (M-L-S(p)-P-D) derived from Human p53. as the immunogen. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi This antibody has been validated on ELISA, WB, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePeptide sequence around phosphorylation site of serine 46 (M-L-S(p)-P-D) derived from Human p53.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied at 1.0mg\/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232864993,"sku":"BLC-05614A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA945066-WB-1.jpg?v=1738833995"},{"product_id":"human-tp53-polyclonal-antibody-blc-05615a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Peptide sequence around phosphorylation site of serine 33 (V-L-S(p)-P-L) derived from Human p53. as the immunogen. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi This antibody has been validated on ELISA, WB, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePeptide sequence around phosphorylation site of serine 33 (V-L-S(p)-P-L) derived from Human p53.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied at 1.0mg\/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138232963297,"sku":"BLC-05615A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA029276-WB-1.jpg?v=1738834001"},{"product_id":"human-tp53-polyclonal-antibody-blc-05616a","title":"Rabbit anti-Human TP53 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53 was raised in rabbit using the Peptide sequence around phosphorylation site of serine 15 (P-L-S(p)-Q-E) derived from Human p53. as the immunogen. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePeptide sequence around phosphorylation site of serine 15 (P-L-S(p)-Q-E) derived from Human p53.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied at 1.0mg\/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233028833,"sku":"BLC-05616A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA157242-WB-1.jpg?v=1738834008"},{"product_id":"human-tp53bp2-polyclonal-antibody-blc-04288a","title":"Rabbit anti-Human TP53BP2 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53BP2 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53BP2 was raised in rabbit using the Fusion protein of Human TP53BP2 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ13625\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman, Mouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53BP2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e53BP2 antibody; Apoptosis stimulating of p53 protein 2 antibody; Apoptosis stimulating protein of p53 2 antibody; Apoptosis-stimulating of p53 protein 2 antibody; ASPP2 antibody; ASPP2_HUMAN antibody; BBP antibody; Bcl2 binding protein antibody; Bcl2-binding protein antibody; NY REN 51 antigen antibody; p53 binding protein 2 antibody; p53-binding protein 2 antibody; p53BP2 antibody; PPP1R13A antibody; Renal carcinoma antigen NY-REN-51 antibody; Tp53bp2 antibody; Tumor protein p53 binding protein 2 antibody; Tumor suppressor p53 binding protein 2 antibody; Tumor suppressor p53-binding protein 2 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFusion protein of Human TP53BP2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233159905,"sku":"BLC-04288A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA948343-P.jpg?v=1738834015"},{"product_id":"human-tp53bp2-polyclonal-antibody-blc-04289a","title":"Rabbit anti-Human TP53BP2 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53BP2 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53BP2 was raised in rabbit using the Fusion protein of Human TP53BP2 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ13625\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman, Mouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53BP2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e53BP2 antibody; Apoptosis stimulating of p53 protein 2 antibody; Apoptosis stimulating protein of p53 2 antibody; Apoptosis-stimulating of p53 protein 2 antibody; ASPP2 antibody; ASPP2_HUMAN antibody; BBP antibody; Bcl2 binding protein antibody; Bcl2-binding protein antibody; NY REN 51 antigen antibody; p53 binding protein 2 antibody; p53-binding protein 2 antibody; p53BP2 antibody; PPP1R13A antibody; Renal carcinoma antigen NY-REN-51 antibody; Tp53bp2 antibody; Tumor protein p53 binding protein 2 antibody; Tumor suppressor p53 binding protein 2 antibody; Tumor suppressor p53-binding protein 2 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFusion protein of Human TP53BP2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233553121,"sku":"BLC-04289A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA287469-P.jpg?v=1738834024"},{"product_id":"human-tp53i11-polyclonal-antibody-blc-03066a","title":"Rabbit anti-Human TP53I11 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53I11 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53I11 was raised in rabbit using the Synthetic peptide of Human TP53I11 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eO14683\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman, Mouse, Rat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53I11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53I11; PIG11; Tumor protein p53-inducible protein 11; p53-induced gene 11 protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic peptide of Human TP53I11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233651425,"sku":"BLC-03066A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA100892-P.jpg?v=1738834032"},{"product_id":"human-tp53i3-polyclonal-antibody-blc-05762a","title":"Rabbit anti-Human TP53I3 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53I3 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53I3 was raised in rabbit using the Recombinant Human Quinone oxidoreductase PIG3 protein (163-332AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ53FA7\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53I3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53 induced gene 3 protein antibody; p53-induced gene 3 protein antibody; Putative quinone oxidoreductase antibody; QORX_HUMAN antibody; quinone oxidoreductase homolog antibody; Quinone oxidoreductase PIG3 antibody; TP53I3 antibody; Tumor protein p53 inducible protein 3 antibody; Tumor protein p53-inducible protein 3 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Quinone oxidoreductase PIG3 protein (163-332AA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS with 0.02% sodium azide, 50% glycerol, pH7.3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233749729,"sku":"BLC-05762A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA687492ESR1HU-IHC-1.jpg?v=1738834042"},{"product_id":"human-tp53inp1-polyclonal-antibody-blc-03175a","title":"Rabbit anti-Human TP53INP1 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human TP53INP1 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against TP53INP1 was raised in rabbit using the Synthetic peptide of Human TP53INP1 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ96A56\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53INP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eDKFZp434M1317 antibody; FLJ22139 antibody; p53 damage inducible nuclear protein 1 antibody; p53 dependent damage inducible nuclear protein 1 antibody; p53 inducible nuclear protein 1 antibody; p53 inducible p53DINP1 antibody; p53-dependent damage-inducible nuclear protein 1 antibody; p53DINP1 antibody; SIP antibody; Stress induced protein antibody; Stress-induced protein antibody; T53I1_HUMAN antibody; Teap antibody; TP53 DINP1 antibody; TP53 INP1 antibody; TP53DINP1 antibody; TP53INP1 antibody; TP53INP1A antibody; TP53INP1B antibody; Tumor protein p53 inducible nuclear protein 1 antibody; Tumor protein p53-inducible nuclear protein 1 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic peptide of Human TP53INP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138233913569,"sku":"BLC-03175A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA052632-P.jpg?v=1738834049"},{"product_id":"tp53-recombinant-monoclonal-antibody-blc-06552a","title":"TP53 Recombinant Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53 Recombinant Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant antibody against TP53 was produced using the Recombinant Human TP53 protein as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IF, FC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human TP53 protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAffinity-chromatography purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IF, FC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138409386209,"sku":"BLC-06552A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-RA024077MA1HU-WB-1.jpg?v=1738838805"},{"product_id":"tp53-recombinant-monoclonal-antibody-blc-06669a","title":"TP53 Recombinant Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53 Recombinant Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant antibody against TP53 was produced using a synthesized peptide derived from human Mutant p53 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53), TP53, P53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eA synthesized peptide derived from human Mutant p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAffinity-chromatography purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138409517281,"sku":"BLC-06669A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-RA825742A0HU-WB.jpg?v=1738838813"},{"product_id":"tp53-recombinant-monoclonal-antibody-blc-06696a","title":"TP53 Recombinant Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53 Recombinant Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant antibody against TP53 was produced using a synthesized peptide derived from human p53 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP04637\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53), TP53, P53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eA synthesized peptide derived from human p53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAffinity-chromatography purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138409615585,"sku":"BLC-06696A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-RA236796A0HU-WB.jpg?v=1738838823"},{"product_id":"recombinant-human-pdrg1-protein-blt-02197p","title":"Human PDRG1 (P53 And Dna Damage-Regulated Protein 1) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human PDRG1 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human PDRG1 protein includes amino acids 1-133aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ9NUG6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53 and DNA damage-regulated protein 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDRG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53 and DNA-damage regulated 1, C20orf126, PDRG.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e17.6 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-133aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eEpigenetics And Nuclear Signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMay play a role in chaperone-mediated protein folding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCytoplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePrefoldin subunit beta family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePredominantly expressed in normal testis and exhibits reduced but detectable expression in other organs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46700675891425,"sku":"BLT-02197P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs11fg5gtng1k8oj.jpg?v=1753337588"},{"product_id":"recombinant-human-tp53aip1-protein-blt-03101p","title":"Human TP53AIP1 (P53-Regulated Apoptosis-Inducing Protein 1) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human TP53AIP1 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human TP53AIP1 protein includes amino acids 1-124aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ9HCN2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ep53-regulated apoptosis-inducing protein 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53AIP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP53-regulated apoptosis-inducing protein 1 isoform a, TPIP1, P53AIP1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e15.0 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-124aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell Biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMay play an important role in mediating p53\/TP53-dependent apoptosis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMitochondrion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eOnly found to be expressed in thymus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701055770849,"sku":"BLT-03101P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1fqmik1laqqpaj.jpg?v=1753341414"},{"product_id":"recombinant-human-tp53i3-protein-blt-03102p","title":"Human TP53I3 (Quinone Oxidoreductase Pig3) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human TP53I3 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human TP53I3 protein includes amino acids 1-332aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ53FA7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQuinone oxidoreductase PIG3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTP53I3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePIG3, Quinone oxidoreductase PIG3 p53 induced gene 3 protein, Putative quinone oxidoreductase, quino\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e37.6 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-332aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701055901921,"sku":"BLT-03102P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1fqv7m1lbrd89j.jpg?v=1753341418"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/collections\/Protein_CD47_PDB_2JJS_8726d859-448c-46ca-952c-dec1bd431cc7.png?v=1778548696","url":"https:\/\/www.betalifesci.com\/collections\/p53-protein-overview-applications-selection-guide.oembed?page=2","provider":"Beta LifeScience","version":"1.0","type":"link"}